# Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

> **NCT03498612** · PHASE2 · TERMINATED · sponsor: **University of Washington** · enrollment: 9 (actual)

## Conditions studied

- Follicular Lymphoma
- Indolent B-Cell Non-Hodgkin Lymphoma
- Marginal Zone Lymphoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03498612
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-09
- **Primary completion:** 2021-06-09
- **Final completion:** 2024-08-29
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Closed per SRC Low Accrual Policy.
- **Last updated:** 2025-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03498612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03498612, "Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03498612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*